Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillaume Dachy

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
JAMA Dermatology|April 25, 2019
Association of PDGFRB Mutations With Pediatric Myofibroma and MyofibromatosisGuillaume Dachy, Ronald R de Krijger, Sylvie Fraitag, et al.
Human Molecular Genetics|March 24, 2017
PDGFRB gain-of-function mutations in sporadic infantile myofibromatosisFlorence A Arts, Raf Sciot, Bénédicte Brichard, et al.
Bone Marrow Transplantation|April 9, 2025
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeGuillermo Ortí, Guillaume Dachy, Charlotte E Graham, et al.
Bone Marrow Transplantation|June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AMLGuillaume Dachy, Myriam Labopin, Gérard Socié, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
Familial Cancer|September 5, 2020
Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working GroupSimone Hettmer, Guillaume Dachy, Guido Seitz, et al.
Bone Marrow Transplantation|January 25, 2025
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortiumOlivier Boyer, Daniele Bensoussan, Halvard Bönig, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 22, 2020
Inflammation-induced cholestasis in cancer cachexiaMorgane M Thibaut, Martina Sboarina, Martin Roumain, et al.
Bone Marrow Transplantation|June 6, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMTGuillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, et al.
Bone Marrow Transplantation|July 17, 2024
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft projectLars Klingen Gjærde, Oscar Brück, Nico Gagelmann, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
JAMA Dermatology|April 25, 2019
Association of PDGFRB Mutations With Pediatric Myofibroma and MyofibromatosisGuillaume Dachy, Ronald R de Krijger, Sylvie Fraitag, et al.
Human Molecular Genetics|March 24, 2017
PDGFRB gain-of-function mutations in sporadic infantile myofibromatosisFlorence A Arts, Raf Sciot, Bénédicte Brichard, et al.
Bone Marrow Transplantation|April 9, 2025
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeGuillermo Ortí, Guillaume Dachy, Charlotte E Graham, et al.
Bone Marrow Transplantation|June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AMLGuillaume Dachy, Myriam Labopin, Gérard Socié, et al.
The Lancet. Oncology|April 3, 2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeCharlotte E Graham, Roser Velasco, Ana Alarcon Tomas, et al.
Familial Cancer|September 5, 2020
Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working GroupSimone Hettmer, Guillaume Dachy, Guido Seitz, et al.
Bone Marrow Transplantation|January 25, 2025
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortiumOlivier Boyer, Daniele Bensoussan, Halvard Bönig, et al.
Journal of Cachexia, Sarcopenia and Muscle|December 22, 2020
Inflammation-induced cholestasis in cancer cachexiaMorgane M Thibaut, Martina Sboarina, Martin Roumain, et al.
Bone Marrow Transplantation|June 6, 2026
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMTGuillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, et al.
Bone Marrow Transplantation|July 17, 2024
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft projectLars Klingen Gjærde, Oscar Brück, Nico Gagelmann, et al.
Pageof 3